Parallax Volatility Advisers’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Parallax Volatility Advisers’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,221	Closed	-$356K	–	3511
2022 Q3	$356K	Buy	+5,221	New	+$288K	﹤0.01%	2105
2021 Q4	–	Sell	-8,593	Closed	-$266K	–	2468
2021 Q3	$219K	Buy	+8,593	New	+$253K	﹤0.01%	1683
2019 Q4	–	Sell	-17	Closed	-$1K	–	2733
2019 Q3	$1K	Buy	+17	New	+$886	﹤0.01%	2240
2019 Q2	–	Sell	-2,007	Closed	-$115K	–	4029
2019 Q1	$106K	Sell	2,007 -7,615	-79%	-$374K	﹤0.01%	2102
2018 Q4	$395K	Sell	9,622 -49,738	-84%	-$1.86M	﹤0.01%	1572
2018 Q3	$2.26M	Sell	59,360 -20,468	-26%	-$907K	﹤0.01%	985
2018 Q2	$3.61M	Buy	+79,828	New	+$3.63M	0.01%	727
2018 Q1	–	Sell	-23,330	Closed	-$918K	–	4740
2017 Q4	$918K	Buy	+23,330	New	+$871K	﹤0.01%	1221
2016 Q3	–	Sell	-1,200	Closed	-$20K	–	4193
2016 Q2	$20K	Buy	+1,200	New	+$24.2K	﹤0.01%	2316

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Parallax Volatility Advisers's GBT Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 5,221 shares — an estimated $356K sold.

Parallax Volatility Advisers first reported a position in GBT in Q2 2016 and held it in 9 quarters. The position peaked at $3.61M in Q2 2018. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Parallax Volatility Advisers reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 5,221 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $356K.
Parallax Volatility Advisers first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 9 quarters.
Parallax Volatility Advisers's Global Blood Therapeutics, Inc. position peaked at $3.61M in Q2 2018.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.